We have partnered, either directly or through our collaborator network, with several companies who are at some level of the supply chain for cannabinoids, or medical cannabis products for research purposes.
Ecofibre is one of Australia’s leading industrial hemp producers. It sources volumes of primary extract of several different cultivars of industrial hemp. Ecofibre grows, harvests, and produces primary extracts from the hemp varieties, and we perform secondary extractions, isolation and refinements of cannabinoids for its pre-clinical research program.
Tilray is one of Canada’s leading medical cannabis suppliers, to source medical cannabis products that meet the Good Manufacturing Practice standards of Australia’s Therapeutic Goods Administration (TGA) and the standards set out in TGA Order #93 for medical cannabis products, as well as matching placebos for their various products. We have both a direct and indirect relationship with Tilray. The company provides: raw cannabis flower for our vaporisation study in driving; refined whole plant extract pharmaceutical grade cannabidiol oil to a Lambert experimental PTSD trial; and supplies 1:1 THC:CBD capsules to our partner network for clinical trial of Chemotherapy-Induced Nausea and Vomiting with the Chris O’Brien Lifehouse cancer research centre.
Bedrocan Holland is the sole supplier of medical cannabis products to the Dutch health ministry. It also provides cannabis flower that meet the Good Manufacturing Practice standards of Australia’s Therapeutic Goods administration and the standards set out in TGA Order #93 for medical cannabis products, as well as matching placebo. This partnership is through our collaborative network with the Palliative Care Clinical Studies Collaborative.
Based in the Netherlands, Echo Pharmaceuticals BV produces a pure, natural THC tablet, Namisol®. It also meets standards for TGA Order #93, and as matching placebo. This partnership is through our collaborative network with the Palliative Care Clinical Studies Collaborative.
Based in the UK, GW Pharmaceuticals provides Epidiolex (cannabidiol oil) and an experimental drug, Cannabidivarin (CBDV) to our partner network in the Sydney Children’s Hospital Network. They are used for clinical activities relating to paediatric epilepsy, as well as to our partner network in Queensland Health for clinical activity in paediatric neurology. In addition, GW Pharmaceuticals provides Sativex to our partner network within the South East Sydney Local Health District for studies into Cannabinoid Replacement Therapy.
Based in Vienna, Trigal Pharma Ltd provides pure cannabidiol capsules and matching placebo to our partner network in the youth anxiety study with Orygen Youth Mental Health team in Melbourne.
We are open to engagement in partnerships with commeracial entities who can supply cannabinoid compounds to our pre-clinical research pipeline, or supply medical cannabis products to GMP standards that meet the TGA’s quality requirements for medical cannabis products for human therapeutic use (TGA Order #9). Regarding medicines for clinical trials, the provision of matching placebo is always a bonus.